US FDA Approves Tiziana's Treatment for Multiple Sclerosis

India Pharma Outlook Team | Friday, 20 October 2023

 India Pharma Outlook Team

Tiziana Life Sciences Ltd., a biotechnology firm researching innovative immunomodulation medicines, has reported a significant milestone in the treatment of multiple sclerosis. The US Food and Drug Administration (FDA) have approved Intranasal Foralumab, a ground-breaking medication created by Tiziana Life Sciences, for patients to take home and self-administer. In consultation with the FDA, delivery device training materials have been created and revised, and patients will be instructed in the use of the nasal device in line with these materials. A new biologic medication, intranasal Foralumab, has shown exceptional promise in the treatment of multiple sclerosis.

The FDA's decision to enable patients to self-administer this medicine at home is an important step forward in the accessibility and convenience of care for people living with this difficult condition, as per pharmabiz. “In the past, MS sufferers had to go to healthcare institutions for treatment, which might be cumbersome and time-consuming.”The FDA's approval for home dosing of Foralumab will transform the way patients manage their condition, giving them greater control over their treatment schedules and the convenience of receiving care in their familiar environment," commented Gabriele Cerrone, Chairman, acting CEO, and founder of Tiziana Life Sciences, on this landmark decision, saying, "We are overjoyed with the FDA's allowance for home dosing of Intranasal Foralumab."This action is very much in line with our aim of making breakthrough medicines more available to patients and, as a result, improving their quality of life. We hope that this therapy method will change the way people with multiple sclerosis manage their illness

© 2024 India Pharma Outlook. All Rights Reserved.